Answers are grounded in this paper and cite their sources.
Validation of a comprehensive assessment tool for hereditary amyloidosis with enhanced early sensitivity, indicating unmet needs in treatment.
The mKS provides a validated comprehensive assessment tool for ATTRv amyloidosis with enhanced early-stage sensitivity and independent organ-specific subscales, addressing critical unmet needs in the era of disease-modifying therapies.
No takes yet. Share an insight, caveat, or question.
Yamakawa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: